相关临床试验
1133
84 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1754
终止
141
12.4%
招募中
170
15.0%
暂停
7
0.6%
撤回
51
4.5%
进行中（未招募）
43
3.8%
Unknown
5
0.4%
已完成
675
59.6%
Enrolling By Invitation
13
1.1%
尚未招募
28
2.5%
暂无批准数据
- Adrian Bird and Huda Zoghbi will receive the 2026 Louisa Gross Horwitz Prize from Columbia University for pioneering work on epigenetic regulation in neurological disease, particularly Rett syndrome. - Their discoveries established the first direct link between epigenetics and a severe neurological disorder, showing that MeCP2 mutations cause Rett syndrome. - The work demonstrated that Rett syndrome is reversible, inspiring gene replacement (TSHA-102, NGN-401) and RNA-regulating (ION 440) therapies now in clinical trials. - Bird and Zoghbi are the 122nd and 123rd Horwitz Prize winners; 55 of the previous 121 winners later received Nobel Prizes.
- A multi-organ chip developed at Columbia Engineering is the first model of its kind to mimic how cancer cells spread from vascular flow to distant organs. - The platform uses engineered human bone and lung tissues linked by vascular circulation to study organ colonization by circulating breast cancer cells. - The chip reproduced organ-specific metastasis patterns and pre-metastatic niche formation, where cancer cells condition target tissues before colonizing them. - The human, patient-specific model offers a new approach methodology that could reveal molecular pathways and therapeutic targets for metastasis.
- Columbia University researchers developed topology-based biomarkers that transform visual tissue patterns into quantitative measurements for breast cancer prognosis. - Higher topology scores, indicating more organized tissue structure, were strongly associated with longer survival and more favorable outcomes across diverse patient populations. - The biomarkers outperformed conventional approaches and remained predictive across both non-Hispanic Black and non-Hispanic white patient groups, showing less variability than traditional methods. - Researchers aim to apply these computational methods to standard pathology slides, potentially expanding access to advanced cancer diagnostics in low-resource settings.
- Researchers at Columbia University captured the first high-resolution 3D structure of the malaria parasite's moving junction, revealing it actively remodels host cell membranes rather than serving as a passive doorway. - The structure, described as sailboat-shaped with AMA1 forming the "sail" and RON proteins the "hull," uses positively charged anchors and wedge-like helices to deform and penetrate the red blood cell membrane. - Using the structure as a blueprint, the team designed a mini-protein inhibitor that blocks parasite invasion in a dose-dependent manner without affecting already-infected cells, offering proof of concept for a new class of antimalarials. - Malaria kills roughly 600,000 people annually, mostly young children in sub-Saharan Africa, and the parasite is increasingly resistant to frontline drugs, making this conserved invasion machinery a high-priority therapeutic target.
- Researchers developed a novel imaging mass spectrometry method to map and quantify toxic lipids HexCer and psychosine across brain regions in a GLD mouse model, revealing spatial distribution patterns previously unknown. - Psychosine (HexSP) buildup was found to begin earlier than HexCer accumulation, with high concentrations in the cerebellum and posterior brain regions associated with disrupted myelin, neuronal damage, and inflammation. - The findings suggest that targeting stem cell therapies to the cerebellum, where fine motor skills are affected, could potentially deplete toxic psychosine levels and positively impact patient outcomes. - The study, published in the Journal of Lipid Research by Columbia University and University of Florida researchers, offers a new approach linking toxic lipid levels directly to neuronal damage over the disease course.
- Researchers at Columbia University have used base editing to make precise single-letter DNA changes in healthy human embryos for the first time, targeting genes linked to cholesterol and blood disorders. - The study demonstrated successful editing in up to three-quarters of cells with no unwanted changes in one case, but mosaicism — where not all cells carry the edit — remains a critical barrier to clinical use. - Scientists emphasize the technology is not ready for the clinic, citing risks including embryo damage from excessive mRNA doses and the inability to confirm non-mosaic embryos through single-cell testing. - Ethicists warn the work could accelerate interest in non-medical embryo editing for "baby improvement," though researchers stress that IVF with genetic screening already addresses most heritable disease prevention needs.
- Entropy Neurodynamics reported breakthrough Phase 2a results showing 75% of treatment-resistant IBS patients achieved clinically meaningful improvements with oral psilocybin plus structured psychotherapy. - The response rate significantly exceeded the 17-44% typically observed with approved IBS therapies, with IBS-C subtype showing 100% response rate. - Study findings demonstrated strong correlation between symptom improvements and psychological mechanisms, supporting gut-brain axis targeting rather than symptom masking. - Results are being used to de-risk development of TRP-8803, the company's proprietary intravenous psilocin formulation designed for improved therapeutic control.
- Silo Pharma expects to commercially launch its QwikAgents enterprise AI agent platform within 60 to 90 days, positioning the company to begin generating initial revenue. - The company is completing a drug-device robustness study for SPC-15, its intranasal PTSD therapeutic candidate, with results expected within approximately 60 days. - Silo plans to request a Type C meeting with the FDA following the robustness study, ahead of an anticipated Investigational New Drug (IND) submission for SPC-15. - SPC-15 is a preclinical intranasal serotonin 5-HT4 receptor agonist being developed for PTSD and anxiety, utilizing a microchip-based nasal spray delivery system for rapid brain targeting.
- Supira Medical received FDA approval to initiate the SUPPORT II pivotal trial, a randomized controlled study designed to assess the safety and efficacy of their next-generation percutaneous ventricular assist device (pVAD) in high-risk percutaneous coronary intervention patients. - The trial will enroll up to 385 patients at up to 40 U.S. sites and represents a critical step toward U.S. market entry through a future PMA submission. - The company has demonstrated advances in cardiogenic shock treatment with recent case experience utilizing percutaneous axillary access to enable patient ambulation with an active 10Fr pVAD. - Supira appointed medical device industry veteran D. Keith Grossman to its Board of Directors to strengthen its commercial foundation as it prepares for market readiness and growth.
- Researchers at Texas Biomedical Research Institute are testing what could become the first therapeutic treatment for measles virus, addressing a critical gap in current medical care. - The monoclonal antibody candidate, known as mAb 77, targets viral proteins to prevent the measles virus from entering human cells and will be tested in juvenile rhesus monkeys next month. - Currently no specific FDA-approved antiviral treatment exists for measles, with doctors relying only on supportive care like fluids, fever reducers, and antibiotics for secondary infections. - The research comes as measles cases surge past levels not seen since 1991, threatening the U.S.'s elimination status achieved in 2000 due to declining vaccination rates.
